Register
A new treatment for osteoporosis in postmenopausal women at high risk of fracture |
Clinical News
eMediNexus Coverage from: 
A new treatment for osteoporosis in postmenopausal women at high risk of fracture
eMediNexus,  11 April 2019
remove_red_eye 574 Views
#Obstetrics and Gynecology #Orthopedics #Pharmacist #Rheumatology

0 Read Comments                

The US Food and Drug Administration (FDA) has approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are women with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies.
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!